About ConcePTION

ConcePTION is a project funded by the Innovative Medicines Initiative, a private public partnership. The project was launched in April 2019.

We believe that we have an important societal obligation to radically and rapidly reduce uncertainty about the effects of medication used during pregnancy and breastfeeding to benefit women in making informed decisions about medications used before, during and after pregnancy.

Reporting medicine use in pregnancy

Did you use any medicines when you were pregnant? Here is how you and your health care provider can report what we call an exposure.

Ten principles for stakeholder engagement in the ConcePTION project

The ConcePTION project is building much-needed knowledge for women and health care professionals. To achieve our goal of building an ecosystem for medicine safety in pregnancy and breastfeeding, we need to engage with women, their partners, their doctors, pharmacists, midwives and nurses, the companies that develop medicines and the authorities that approve them and decide what becomes available to patients. Our goal is to work in an open and inclusive way, with the spirit of mutual respect and trust. Here is how we engage with stakeholders in an ethical way.


Recommendations for the adequate doses for medication in pregnancy are often missing. This can lead to suboptimal care. As part of Project MADAM (Model-Adjusted Doses for All Mothers), researchers are using new kinds of evidence to issue dose recommendations for pregnant women. You can also contribute by helping the MADAM project to share their surveys with healthcare practitioners and pregnant women! | READ MORE >>
To be able to provide evidence for how a medicine transfers to breastmilk, we need to test milk from mothers who use medicines during the post-partum period. In case you missed our webinar on the ConcePTION European Breast Milk Collection in May this year, we are now sharing a recording of the presentations! | READ MORE >>
The label on most medicines are missing information on safety in pregnancy and breastfeeding. To address this gap, pharmaceutical companies are requested to develop post-approval studies to assess safety. But even when companies carry out these post approval observational studies to generate evidence of safety data, a landscape study from the ConcePTION project published in Drug Safety, shows that the results rarely make it to the product label.  | READ MORE >>

The ConcePTION consortium

The project unites an unprecedented 88 organizations from 22 countries, including the European Medicines Agency, drug manufacturers, academia, public health organizations, and teratology networks to innovate new solutions to a decades-long public health issue.


The ConcePTION project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821520. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.